Screener
Travere Therapeutics, Inc. TVTX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net product sales | $124,492 | $75,861 |
| License and collaboration revenue | 2,707 | 5,871 |
| Total revenue | 127,199 | 81,732 |
| Operating expenses: | ||
| Cost of goods sold | 1,950 | 4,679 |
| Research and development | 57,094 | 46,889 |
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s total revenue?
- Travere Therapeutics, Inc. (TVTX) reported total revenue of $127.2M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total revenue changed year-over-year?
- Travere Therapeutics, Inc.'s total revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total revenue?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s total revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Travere Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude